The histone deacetylase inhibitor romidepsin is a potential therapeutic for metastatic osteosarcoma

被引：0
作者：
Seiden, Emily E.
Richardson, Spencer M.
Ramnath, Shrey
Whiteside, Tia
Coy, Kathryn L.
Sinn, Anthony L.
Capitano, Maegan L.
Pollok, Karen E.
Collier, Chris D.
Greenfield, Ed M.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-7554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7554
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Synergistic Prostate Cancer Targeted Radiosensitization by Gold Nanoparticles and Histone Deacetylase Inhibitor Romidepsin
    Hara, D.
    Ma, W.
    Tao, W.
    Dogan, N.
    Pollack, A.
    Ford, J.
    Shi, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E521 - E522
  • [22] Histone Deacetylase Inhibitor Romidepsin Inhibits De Novo HIV-1 Infections
    Jonsson, Kasper L.
    Tolstrup, Martin
    Vad-Nielsen, Johan
    Kjaer, Kathrine
    Laustsen, Anders
    Andersen, Morten N.
    Rasmussen, Thomas A.
    Sogaard, Ole S.
    Ostergaard, Lars
    Denton, Paul W.
    Jakobsen, Martin R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (07) : 3984 - 3994
  • [23] Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy
    Pojani, Eftiola
    Barlocco, Daniela
    CURRENT MEDICINAL CHEMISTRY, 2021, 28 (07) : 1290 - 1303
  • [24] THERAPEUTIC EFFECTS OF ROMIDEPSIN, A HISTONE DEACETYLASE INHIBITOR (HDACI), ALONE AND IN COMBINATION WITH NATURAL KILLER CELLS AGAINST PEDIATRIC BURKITT LYMPHOMA
    Chu, Y.
    Yahr, A.
    Ayello, J.
    vandeven, C.
    Cairo, M.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S138 - S138
  • [25] Selective histone deacetylase 6 inhibitors as a potential therapeutic option for metastatic uveal melanoma
    Sundaramurthi, Husvinee
    Mulero, Sandra Garcia
    Piulats, Josep
    Watson, William
    Tobin, Desmond
    Kennedy, Breandan
    BRITISH JOURNAL OF PHARMACOLOGY, 2021, 178 (24) : 4982 - 4983
  • [26] Evaluation of the Therapeutic Potential of Histone Deacetylase 6 Inhibitors for Primary and Metastatic Uveal Melanoma
    Sundaramurthi, Husvinee
    Giricz, Zoltan
    Kennedy, Breandan N.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (16)
  • [27] Insights into the therapeutic potential of histone deacetylase inhibitor/immunotherapy combination regimens in solid tumors
    Sedky, Nada K.
    Hamdan, Alyaa A.
    Emad, Salma
    Allam, Aya L.
    Ali, Mohamed
    Tolba, Mai F.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24 (07) : 1262 - 1273
  • [28] Improving therapeutic potential in breast cancer via histone deacetylase inhibitor loaded nanofibrils
    Senthilkumar, Praveetha
    Gogoi, Bhaskar
    Dhan, Swati Smita
    Subramani, Ramesh
    Pushparaj, Charumathi
    Mahesh, Ayyavu
    DRUG DEVELOPMENT RESEARCH, 2024, 85 (02)
  • [29] Insights into the therapeutic potential of histone deacetylase inhibitor/immunotherapy combination regimens in solid tumors
    Nada K. Sedky
    Alyaa A. Hamdan
    Salma Emad
    Aya L. Allam
    Mohamed Ali
    Mai F. Tolba
    Clinical and Translational Oncology, 2022, 24 : 1262 - 1273
  • [30] Trichostatin A - histone deacetylase inhibitor with clinical therapeutic potential - is also a selective and potent inhibitor of gelatinase A expression
    Ailenberg, M
    Silverman, M
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 298 (01) : 110 - 115
12345